Following on from information provided to NICE by the company in June 2019, the appraisal of Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1466 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2019, the appraisal of Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 June 2019 | The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal which closed on 22 May 2019. The company that manufacturer depatuxizumab mafodotin have advised NICE that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information NICE will not be progressing with the scoping exercise at this time. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course if required. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk) |
| 21 March 2017 | Referral |
| 21 March 2017 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual